Clinical trial NCT03275012: Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain
Official title: Randomized, Double-blind, Placebo Controlled, Superiority Phase II Study to Evaluate the Safety, Pharmacokinetic, Efficacy of Gabapentin as add-on to Morphine in Children From 3 Months to Less Than 18 Years
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Chronic Pain
Lead sponsor: Pharmaceutical Research Management srl
Sponsor class: INDUSTRY
Collaborators: name: European Commission
First posted: 2017-09-07
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the efficacy of gabapentin as adjunctive therapy to morphine in the treatment of severe chronic neuropathic or mixed pain in children from 3 months to less than 18 years of age assessed by the difference in average pain scores between treatment arms at the end of the treatment period.

Detailed description: This paediatric trial has the objective to make gabapentin available for children with severe chronic neuropathic or mixed pain. This study will be conducted in full conformance with the ethical principles outlined in the Declaration of Helsinki, consistent with ICH-GCP (including ICH Topic E11 guideline) and applicable regulatory requirements including the Paediatric Recommendations (CE/2008).

Gabapentin has been successfully used to treat neuropathic pain in adults. In absence of specific paediatric studies it is not approved for the same condition in children.

The paediatric use of gabapentin is hampered by: a) the lack of a suitable paediatric formulation, b) the significant variability of gabapentin PK profile and c) efficacy and safety data in this specific population.

GABA-2 is a superiority trial designed to assess the potential benefit of gabapentin oral solution in augmenting the analgesic effect of morphine in children affected by severe chronic pain thus preventing or decreasing opioid tolerance, as it has been reported to happen in adults. Thus GABA-2 study is an randomized, double blind, placebo controlled, multi-centre study to evaluate the efficacy of gabapentin added to morphine in paediatric patients suffering from severe chronic pain (neuropathic or mixed with ascertained neuropathic component). The trial will include 66 patients aged from 3 months to less than 18 years affected by severe chronic neuropathic or mixed pain and in need of morphine.

Children from 3 months to \<3 years of age will participate to GABA-2 on the basis of the nature of the underlying disease suggestive of a neuropathic component.

A block randomisation will be applied to assign children to gabapentin and morphine (intervention group) or gabapentin placebo and morphine (control group) in a 1:1 ratio.

Randomisation will be stratified by age-group as follows:

* 3 months - \< 3 years;
* 3 years - \< 8 years;
* 8 years - \< 18 years.

Recruitment will start with patients ≥ 3 years of age. Patients \< than 3 years of age will be recruited when results from the ongoing non-clinical toxicological study in juvenile rats will confirm the safety of gabapentin in the age subset 3 months-3 years.

The protocol has been designed to ensure double-blind conditions at randomisation and throughout the treatment period. Blinding (children, caregiver, outcome assessor) will be ensured by elaborating an identical (matching) gabapentin placebo.

The study comprises 3 stages over 18 to 22 weeks: 1st stage ( screening period of 1 week, wash out phase of max 3 days and baseline assessment of 3 days ), 2nd stage ( treatment period including an optimization phase of 3 weeks and 12 weeks of maintenance), 3rd stage (study taper lasting from 0 to 4 weeks and 1 week follow up).

The proposed formulation of the IMP test is a liquid oral formulation (syrup) containing 75 mg/ml of gabapentin. The IMP comparator is the placebo. The background therapy is morphine presented as immediate and extended-release tablets and a liquid, oral formulation. Every participant will be administered morphine and the active product or placebo.

For both study drugs, dosing will initiate at a starting dose in mg/kg/day and will be increased according to a predefined matrix to a maximum dose in mg/kg/day. Dosing will be flexibly optimised in order to maximise the potential benefits while minimising risk of AEs. There will be a maximum of 5 possible dose adjustments during the 3 weeks optimisation period.

Dosing for gabapentin during the optimization period will be defined according to two weight groups (5-15kg and \>15kg). Current dosing schedule for gabapentin is the following:

* Day 1 starting dose in mg/kg/day;
* Day 3 2 times the starting dose in mg/kg/day;
* Day 5 3 times the starting dose in mg/kg/day;
* Day 14 2 times the dose of Day 5 in mg/kg/day;
* Day 21 3 times the dose of Day 5 in mg/kg/day.

Dosing of morphine is largely based on the "WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses", 2012. The guidelines recommended starting dose for immediate release formulation of morphine are '80-200 mcg/kg every 4 hours for infants and 200-500 mcg/kg in 6 divided doses in older children. ' However, due to compliance issues a four times daily regimen (q.i.d) will be used during the titration phase of this protocol for children with body weight \>30kg and throughout this study for patients with \<30kg body weight.

The morphine starting dose in this study reflects the lower end of the WHO recommendation with a titration scheduled to reach a maximum daily dose of 1.2 mg/kg/day. Patients \< 30kg BW will have the liquid morphine formulation, 4 times daily throughout the study and patients \> 30kg will receive immediate release tablet 4 times daily, during the titration phase and extended release tablets 2 times daily during the maintenance phase.

All subjects that are completing the study or are withdrawn early must be tapered off of the gabapentin. At the visit of Early Termination or End Of Study visit, subjects will be dispensed a taper dose based on their current dose level (the dose of the medicinal product taken during the maintenance period) and should follow the dose tapering as described in the protocol.

Concomitant use of some medications that could interfere with the study will be prohibited. Unrestricted use of paracetamol and/or ibuprofen alone or in combination will be used as rescue therapy any time the patient experiences pain (pain level \>4/10 measured with age- appropriate pain scales FLACC, FPS-R or NRS-11) This study includes pharmacokinetic analysis to establish a population pharmacokinetic model adequate to describe the time-course and variability of plasma concentrations of gabapentin and gabapentin plus morphine following repeat dosing in children with chronic pain.

The study includes also an optional exploratory pharmacogenomics study which requires a separate Informed Consent if the parent of the subject agrees to participate. The aims of the exploratory pharmacogenomic research is to better understand inherited genetic factors and their association with clinical assessments, which may include pharmacokinetics of gabapentin, relative susceptibility to drug-drug interactions, predisposition to side effects, and/or patients' response to treatment with gabapentin.

The study foresees also an exploratory metabolomic study that may provide insight in the mechanism of neuropathic pain and the inter-individual variation in drug response.

During this study, it is expected that a maximum of 15.9 mL of blood will be taken from every subject (male and female). Additional 2.0 ml of blood will be required from females of child bearing age for pregnancy testing.

The primary analysis of efficacy will be conducted using ANCOVA with baseline average pain score as a covariate.

The study will be conducted under the supervision of an independent Data Safety Monitoring Committee (DSMC).

Eligibility criteria: Inclusion Criteria:

1. Male or female, aged 3 months to less than 18 years at screening (V1)
2. Informed consent by parent(s) and/or legal guardian according to each country legal requirement.
3. Assent, where applicable, according to each country legal requirement.Informed (co-) consent of child, where applicable, according to each country legal requirement.
4. Subjects that meet the diagnostic criteria for neuropathic or mixed pain.
5. Subjects that present with chronic pain defined as the recurrent or continuous pain persisting more than 3 months.
6. Subject that present with severe pain as defined by average pain intensity of ≥7 /10 as assessed during a 3-day screening period
7. Stable underlying disease condition and treatment.
8. Patients with Chemotherapy Induced Peripheral Neuropathy, when in clinical remission or maintenance phase of their therapeutic protocol.

Exclusion Criteria:

1. Pain duration of more than 5 years.
2. Current use of gabapentin.
3. Current use of strong opioids (morphine, methadone, fentanyl, ketamine, oxycodone).
4. History of failure to respond to adequate treatment by gabapentin or opioids for neuropathic pain.
5. History of epileptic condition (except febrile seizure disorder).
6. Subjects with diagnosis of sickle cell disease.
7. Subjects that present significant cognitive impairment.
8. Subjects that present current, controlled or uncontrolled, co-morbid psychiatric diagnosis that can impair pain diagnosis and assessment such as severe depressive conditions or psychosis.
9. Subjects with history of or current suicidal ideation or behaviour.
10. Subjects with history of substance abuse in particular opioids.
11. Subjects under prohibited concomitant medication .
12. Subjects with a body mass index (BMI) for age and gender of \< 5th percentile or \> 95th percentile (charts provided as Appendix 3).
13. Subjects with significant renal impairment, i.e., glomerular filtration rate \< 90 mL/min/1.73 m2 (Revised Schwarz equation).
14. Subjects with significant hepatic impairment or with Aspartate Transaminase (AST) or Alanine Transaminase (ALT) enzymes 3 times the upper limit of the age-specific reference range.
15. Subjects in need for corticosteroid oral treatment or corticosteroid infiltrations to treat pain caused by infiltration or compression of neural structures, e.g. peripheral nerves or spinal cord.
16. Subjects with clinically relevant abnormal ECG at the screening visit in the discretion of the Investigator/cardiologist.
17. Subjects with known allergy, hypersensibility or clinically significant intolerance to gabapentin or any component found in the study drugs.
18. Subjects with fructose intolerance, diabetes, glucose-galactose malabsorption or lactase-isomaltase deficiency.
19. Subjects participating in another clinical interventional trial.
20. Subjects scheduled for surgery or in recovery from surgery occurring within 3 months of baseline assessment.
21. Female subjects who are pregnant or currently lactating.
22. Subjects that failed screening or were previously enrolled in this study
23. Patients with Chemotherapy Induced Peripheral Neuropathy, when in induction phase of their therapeutic protocol

Primary outcomes:
measure: Pain scores
timeFrame: on average of 16 weeks
Secondary outcomes:
measure: Percentage of responders to treatments
timeFrame: on average of 16 weeks
measure: Daily pain intensity
timeFrame: an average of 3 weeks
measure: Observational assessment of pain
timeFrame: on average of 16 weeks
measure: Self-assessment of pain for children ≥8 years of age
timeFrame: on average of 16 weeks
measure: Extent of pain
timeFrame: on average of 16 weeks
measure: Number of episodes of breakthrough pain
timeFrame: on average of 15 weeks
measure: Number of rescue interventions required during treatment period
timeFrame: on average of 15 weeks
measure: Number of pain-free days
timeFrame: on average of 15 weeks
measure: Participant dropouts
timeFrame: up to 21 weeks
measure: The total cumulative weight normalized dose of each rescue drug.
timeFrame: on average of 16 weeks
measure: Total Summary Score from PedsQL™ scale
timeFrame: on average of 15 weeks
measure: Physical Health Summary Score from PedsQL™ scale
timeFrame: on average of 15 weeks
measure: Psychosocial Health Summary Score from PedsQL™ scale
timeFrame: on average of 15 weeks
measure: Acceptability of treatment
timeFrame: at week 16
measure: Global satisfaction with treatment
timeFrame: at week 16
measure: Clinical Global Impression of Severity of the subject's condition
timeFrame: an average of 15 weeks
measure: Clinical Global Impression of Improvement for pain
timeFrame: an average of 15 weeks
measure: Patient/parent Global Impression of Change
timeFrame: an average of 12 weeks
measure: CL/F
timeFrame: at week 3 or at week 4 or at week 16
measure: Vd/F
timeFrame: at week 3 or at week 4 or at week 16
measure: ka
timeFrame: at week 3 or at week 4 or at week 16
measure: AUC
timeFrame: at week 3 or at week 4 or at week 16
measure: Cmax
timeFrame: at week 3 or at week 4 or at week 16
measure: Tmax
timeFrame: at week 3 or at week 4 or at week 16
measure: Css
timeFrame: at week 3 or at week 4 or at week 16
measure: Cmin
timeFrame: at week 3 or at week 4 or at week 16
measure: Systemic exposure to investigational product
timeFrame: an average of 12 weeks
measure: Incidence of Adverse Events
timeFrame: up to 21 weeks
measure: Percentage of subjects discontinuing the Trial
timeFrame: up to 21 weeks
measure: Aggressive behaviour in children aged >6 years
timeFrame: an average of 15 weeks
measure: Suicidal ideation/behaviour in subjects aged 6 years and older
timeFrame: an average of 16 weeks
measure: Assessment of blinding
timeFrame: at week 16
Other outcomes:
Locations:
Study officials:
affiliation: Erasmus Medical Center
name: Saskia De Wildt, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010 Jul 14;2:52. doi: 10.3410/M2-52.
citation: Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001 Dec;17(4):284-95. doi: 10.1097/00002508-200112000-00002.
citation: de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN; GAPP consortium. Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial. Trials. 2019 Jan 15;20(1):49. doi: 10.1186/s13063-018-3169-3.